SEO URLwww.firestrike.ai/deals/arcellx-gilead-sciences-acquisition-2026-34
acquisitionAnnounced · Mar 1, 2026biotechnologySource · CredibleArticle · Factual
Gilead Sciences acquires Arcellx
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$7.8B
Target
Arcellx
NASDAQ: ACLX · Redwood City, California
Acquirer
Gilead Sciences
Full Acquisition
Status
Announced
Gilead Sciences agreed to acquire Arcellx. Reported deal value: $7.8B. Status: Announced. Sector: biotechnology. Target headquarters context: Redwood City, California, United States.
This page summarizes publicly available information about the transaction as of 2026-03-01. Figures and status may change as filings and press coverage update.
Bengaluru: Gilead Sciences will pay as much as USD 7.8 billion to acquire partner Arcellx in its largest deal since 2020, the biopharma company said on Monday, as it looks to strengthen its lineup of cancer treatments
Deal timeline
Announced
Mar 1, 2026 · medicaldialogues.in
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotechnology with a reported deal value of $7.8B. Figures and status may change as sources update.
Sources: medicaldialogues.in · Primary article · FireStrike proprietary index